These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9883926)

  • 1. Anti-U and haemolytic disease of the fetus and newborn.
    Smith G; Knott P; Rissik J; de la Fuente J; Win N
    Br J Obstet Gynaecol; 1998 Dec; 105(12):1318-21. PubMed ID: 9883926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pathogenesis of ABO haemolytic disease of the newborn.
    Voak D
    Vox Sang; 1969 Dec; 17(6):481-513. PubMed ID: 5373123
    [No Abstract]   [Full Text] [Related]  

  • 3. [Fetal hemolytic disease in a patient immunized by six antibodies: diagnosis and treatment].
    Tantalo V; Rossi E; Gianotti GA; Morotti R; Zuliani G; Buscaglia M; Galligani M
    Ann Ostet Ginecol Med Perinat; 1990; 111(5):321-5. PubMed ID: 2092607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-D concentration in mother and child in haemolytic disease of the newborn.
    Hughes-Jones NC; Ivona M; Ellis J; Walker W
    Vox Sang; 1971 Aug; 21(2):135-40. PubMed ID: 5000958
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of pregnancies complicated by anti-E alloimmunization.
    Joy SD; Rossi KQ; Krugh D; O'Shaughnessy RW
    Obstet Gynecol; 2005 Jan; 105(1):24-8. PubMed ID: 15625137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe ABO haemolytic disease due to high titre IgG anti-B in an A2 mother.
    Graham H; Morrison M; Casey E
    Vox Sang; 1974; 27(4):363-8. PubMed ID: 4213379
    [No Abstract]   [Full Text] [Related]  

  • 7. [An at-risk pregnancy caused by an irregular complement-activating nonspecific alloantibody in maternal serum].
    Ratei R
    Geburtshilfe Frauenheilkd; 1988 Oct; 48(10):731-2. PubMed ID: 3234706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mononuclear phagocyte assays, autoanalyzer quantitation and IgG subclasses of maternal anti-RhD in the prediction of the severity of haemolytic disease in the fetus before 32 weeks gestation.
    Garner SF; Wiener E; Contreras M; Nicolini U; Kochenour N; Letsky E; Rodeck CH
    Br J Haematol; 1992 Jan; 80(1):97-101. PubMed ID: 1536816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemolytic disease of the newborn due to anti-Mt a .
    Field TE; Wilson TE; Dawes BJ; Giles CM
    Vox Sang; 1972; 22(5):432-7. PubMed ID: 5032416
    [No Abstract]   [Full Text] [Related]  

  • 10. Chromatographic separation and serologic analysis of antibodies in the sera of mothers with ABO incompatibility.
    KuĊ›nierz G
    Arch Immunol Ther Exp (Warsz); 1974; 22(2):161-5. PubMed ID: 4209990
    [No Abstract]   [Full Text] [Related]  

  • 11. Red cell antibodies in pregnancy: there is no 'critical titre'.
    van Dijk BA; Dooren MC; Overbeeke MA
    Transfus Med; 1995 Sep; 5(3):199-202. PubMed ID: 8593524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of feto-maternal red cell allo-immunizations].
    Bricca P; Guinchard E; Guitton Bliem C
    Transfus Clin Biol; 2011 Apr; 18(2):269-76. PubMed ID: 21397546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maternal anti-D concentrations and outcome in rhesus haemolytic disease of the newborn.
    Bowell P; Wainscoat JS; Peto TE; Gunson HH
    Br Med J (Clin Res Ed); 1982 Jul; 285(6338):327-9. PubMed ID: 6284295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous intrauterine transfusion in a case of anti-U.
    Adam S; Lombaard H
    Transfusion; 2016 Dec; 56(12):3029-3032. PubMed ID: 27664105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of anti-Kell sensitization in pregnancy.
    Mayne KM; Bowell PJ; Pratt GA
    Clin Lab Haematol; 1990; 12(4):379-85. PubMed ID: 2081378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Positive Coomb's test in newborns; causes and clinical consequences Summary of cases diagnosed in the Blood Bank in the years 2005 to 2012].
    Kristinsdottir T; Kjartansson S; Hardardottir H; Jonsson T; Halldorsdottir AM
    Laeknabladid; 2016 Jul; 102(7-8):326-31. PubMed ID: 27531851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of immune haemolytic disease in the fetus.
    Tannirandorn Y; Rodeck CH
    Blood Rev; 1991 Mar; 5(1):1-14. PubMed ID: 2032024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory assays for predicting the severity of haemolytic disease of the fetus and newborn.
    Hadley AG
    Transpl Immunol; 2002 Aug; 10(2-3):191-8. PubMed ID: 12216949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of maternal anti-D concentration in predicting the outcome of Rh(D) haemolytic disease.
    Harrison KL; Baker JW; Popper EI; Harden PA
    Aust N Z J Obstet Gynaecol; 1984 Feb; 24(1):6-8. PubMed ID: 6430264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemolytic disease of the newborn because of rare anti-Vel.
    van Gammeren AJ; Overbeeke MA; Idema RN; van Beek RH; Ten Kate-Booij MJ; Ermens AA
    Transfus Med; 2008 Jun; 18(3):197-8. PubMed ID: 18598283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.